{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:06:37Z","timestamp":1790186797547,"version":"4.1.0"},"reference-count":30,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1136\/jnnp-2015-311486","type":"journal-article","created":{"date-parts":[[2015,9,30]],"date-time":"2015-09-30T02:43:15Z","timestamp":1443580995000},"page":"106-112","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":54,"title":["IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia"],"prefix":"10.1136","volume":"88","author":[{"given":"Shawn","family":"Kile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3098-6160","authenticated-orcid":false,"given":"Carol","family":"Parise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"Donnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Hankins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azad","family":"Ghassemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,9,29]]},"reference":[{"key":"key-10.1136\/jnnp-2015-311486-1","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/01.jnen.0000240466.10758.ce","article-title":"Abeta species removal after abeta42 immunization","volume":"65","author":"Nicoll","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"key":"key-10.1136\/jnnp-2015-311486-2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.10253","article-title":"Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease","volume":"52","author":"Dodel","year":"2002","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2015-311486-3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jnr.20886","article-title":"Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide","volume":"84","author":"Istrin","year":"2006","journal-title":"J Neurosci Res"},{"key":"key-10.1136\/jnnp-2015-311486-4","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/jnnp.2003.033399","article-title":"Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease","volume":"75","author":"Dodel","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2015-311486-5","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.neurobiolaging.2007.12.021","article-title":"18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease","volume":"30","author":"Relkin","year":"2009","journal-title":"Neurobiol Aging"},{"key":"key-10.1136\/jnnp-2015-311486-6","unstructured":"Relkin NR . Intravenous immunoglobulin treatment decreases rates of ventricular enlargement and cognitive decline in Alzheimer's disease. Abstract Number P03.294. American Academy of Neurology; 2010 April 14; Toronto."},{"key":"key-10.1136\/jnnp-2015-311486-7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1474-4422(13)70014-0","article-title":"Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"12","author":"Dodel","year":"2013","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2015-311486-8","article-title":"Results of GAP (160701). A phase III study of intravenous gammaglobulin for the treatment of mild to moderate Alzheimer's disease","volume-title":"Alzheimer's Association International Conference","year":"2013"},{"key":"key-10.1136\/jnnp-2015-311486-9","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1212\/WNL.0b013e3181ae7aaf","article-title":"IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders","volume":"73","author":"Fillit","year":"2009","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-311486-10","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1212\/WNL.56.9.1133","article-title":"Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"56","author":"Petersen","year":"2001","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-311486-11","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/archneur.63.5.665","article-title":"Neuropathologic features of amnestic mild cognitive impairment","volume":"63","author":"Petersen","year":"2006","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2015-311486-12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","article-title":"Mild cognitive impairment as a diagnostic entity","volume":"256","author":"Petersen","year":"2004","journal-title":"J Intern Med"},{"key":"key-10.1136\/jnnp-2015-311486-13","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer\u2019 Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"key-10.1136\/jnnp-2015-311486-14","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.neurobiolaging.2010.04.029","article-title":"Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort","volume":"31","author":"Risacher","year":"2010","journal-title":"Neurobiol Aging"},{"key":"key-10.1136\/jnnp-2015-311486-15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"key-10.1136\/jnnp-2015-311486-16","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archneurol.2010.179","article-title":"Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people","volume":"67","author":"De Meyer","year":"2010","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2015-311486-17","unstructured":"IBM SPSS Statistics for Windows program. Armonk, NY: IBM Corp, 2012."},{"key":"key-10.1136\/jnnp-2015-311486-18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2165\/11533070-000000000-00000","article-title":"Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence","volume":"70","author":"Dodel","year":"2010","journal-title":"Drugs"},{"key":"key-10.1136\/jnnp-2015-311486-19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jalz.2010.03.006","article-title":"Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans","volume":"6","author":"Aisen","year":"2010","journal-title":"Alzheimers Dement"},{"key":"key-10.1136\/jnnp-2015-311486-20","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1212\/WNL.0b013e318207b1b9","article-title":"Report of the task force on designing clinical trials in early (predementia) AD","volume":"76","author":"Aisen","year":"2011","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-311486-21","doi-asserted-by":"crossref","first-page":"e47905","DOI":"10.1371\/journal.pone.0047905","article-title":"Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment","volume":"7","author":"Wu","year":"2012","journal-title":"PLoS ONE"},{"key":"key-10.1136\/jnnp-2015-311486-22","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.nicl.2013.04.014","article-title":"Arterial spin labeled MRI in prodromal Alzheimer's disease: a multi-site study","volume":"2","author":"Wang","year":"2013","journal-title":"Neuroimage Clin"},{"key":"key-10.1136\/jnnp-2015-311486-23","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2147\/NDT.S62323","article-title":"Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative","volume":"10","author":"Samtani","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"key-10.1136\/jnnp-2015-311486-24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2009.1064","article-title":"CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment","volume":"302","author":"Mattsson","year":"2009","journal-title":"JAMA"},{"key":"key-10.1136\/jnnp-2015-311486-25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2015-311486-26","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2015-311486-27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10875-007-9088-9","article-title":"Intravenous immunoglobulin: an update on the clinical use and mechanisms of action","volume":"27","author":"Negi","year":"2007","journal-title":"J Clin Immunol"},{"key":"key-10.1136\/jnnp-2015-311486-28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00401-010-0719-5","article-title":"Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis","volume":"120","author":"Boche","year":"2010","journal-title":"Acta Neuropathol"},{"key":"key-10.1136\/jnnp-2015-311486-29","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1742-2094-7-90","article-title":"Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer's disease","volume":"7","author":"Magga","year":"2010","journal-title":"J Neuroinflammation"},{"key":"key-10.1136\/jnnp-2015-311486-30","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.intimp.2013.04.034","article-title":"Intravenous immunoglobulin products contain specific antibodies to recombinant human tau protein","volume":"16","author":"Smith","year":"2013","journal-title":"Int Immunopharmacol"}],"container-title":["Journal of Neurology, Neurosurgery & Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2015-311486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T18:01:05Z","timestamp":1601056865000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2015-311486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,29]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,1,13]]},"published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1136\/jnnp-2015-311486"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2015-311486","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,29]]}}}